Genzyme inks $150M deal for Ceregene therapy

Genzyme has agreed to pay $25 million up front to partner with Ceregene on CERE-120, its experimental lead therapy being developed for Parkinson's disease. Genzyme has also signed up to pay up to $125 million in milestones as well as half of the late-stage development costs for the therapy. In return, Genzyme gets marketing rights outside the U.S. and Canada.

"We look forward to helping further the development of this exciting approach, building on our long-term commitment to gene therapy and neurodegenerative diseases," said David Meeker, president, Lysosomal Storage Disorders unit, Genzyme Corporation. "This program which is focused on preserving neuronal function will complement our existing Parkinson's clinical trial that is currently underway."

- check out the release on the deal

Related Articles:
Genzyme snares cancer therapy in $345M buyout. Report
Genzyme boosts AnorMED bid to $580M. Report
Genzyme sees big returns from small drug market. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.